Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
11.96B
Market cap11.96B
Price-Earnings ratio
267.92
Price-Earnings ratio267.92
Dividend yield
Dividend yield
Average volume
1.05M
Average volume1.05M
High today
High today
Low today
Low today
Open price
$112.53
Open price$112.53
Volume
0.00
Volume0.00
52 Week high
$122.21
52 Week high$122.21
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $110.00. The company's market cap stands at 11.96B, with a P/E ratio of 267.92.

Corcept Therapeutics(CORT) stock opened on 2026-08-14 at $112.53. The price climbed to — and dipped to —.

Corcept Therapeutics(CORT) shares are trading with a volume of 0, against a daily average of 1.05M.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $122.21 at its peak.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $122.21 at its peak.

CORT News

Simply Wall St 3d
Upgraded 2026 Revenue Outlook And Buybacks Might Change The Case For Investing In Corcept - simplywall.st

...

Upgraded 2026 Revenue Outlook And Buybacks Might Change The Case For Investing In Corcept - simplywall.st
Simply Wall St 7d
Corcept Therapeutics Lifted Guidance, Is The Upside Already Priced In?

Advertisement Why Corcept Therapeutics stock is back in focus after Q2 earnings Corcept Therapeutics (CORT) is drawing fresh attention after its July 29 earni...

Corcept Therapeutics Lifted Guidance, Is The Upside Already Priced In?

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
0%
Sell
16.7%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.